Methods and devices for renal nerve blocking

• US 8,771,252 B2
• Filed: 05/20/2005
• Issued: 07/08/2014
• Est. Priority Date: 04/08/2002
• Status: Active Grant

• Current Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Original Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Inventors: Gelfand, Mark, Levin, Howard R.
• Primary Examiner(s): BOCKELMAN, MARK
• Application Number:
  US11/133,925
• Publication Number:
  US 20060025821A1
• Time in Patent Office: 3,336 Days
• Field of Search: 607/3, 604/890.1, 604/891.1, 604/131, 604/151, 604/522, 604/506
• US Class Current: 604/506
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/3605 Implantable neurostimulators for stimulating central or peripheral nerve system
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluting implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.

Claims

1. A method of treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the method comprising:

delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient; and

at least partially blocking neural activity along the nerve with the neuromodulatory agent and modulating at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient,

wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering the neuromodulatory agent via an intravascular to extravascular approach.

2. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering at least one of an anesthetic, neurotoxin, alcohol, phenol, ketamine, and antidepressant to the nerve.

3. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering a neuromodulatory agent via a catheter.

4. The method of claim 3 wherein a distal portion of the catheter comprises at least two electrodes, and wherein the method further comprises sensing neural activity via the electrodes.

5. The method of claim 3 wherein a distal portion of the catheter comprises at least two electrodes, and wherein the method further comprises electrically stimulating a renal nerve of the patient via the electrodes.

6. The method of claim 5 wherein the distal portion of the catheter comprises a first electrode configured to be located proximally of a nerve modulating site and a second electrode configured to be located distally of the nerve modulating site, and wherein the method further comprises sensing neural activity via the first and second electrodes.

7. The method of claim 5 wherein the distal portion of the catheter comprises a first electrode configured to be located proximally of a nerve modulating site and a second electrode configured to be located distally of the nerve modulating site, and wherein the method further comprises electrically stimulating a renal nerve of the patient with the electrodes.

8. The method of claim 1, further comprising determining whether neural activity has been sufficiently altered.

9. The method of claim 1 wherein at least partially blocking the neural activity comprises at least substantially blocking sympathetic neural activity along a renal nerve of the patient.

10. The method of claim 9, further comprising determining whether neural activity along the renal nerve has been substantially blocked.

11. The method of claim 10 wherein determining whether neural activity has been substantially blocked comprises electrically stimulating the renal nerve and detecting a response in the patient.

12. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering a neuromodulatory agent via a drug delivery device.

13. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises positioning a needle within a periarterial space of the patient and injecting the neuromodulatory agent via the needle into the periarterial space of the patient.

14. The method of claim 13 wherein positioning a needle proximate the periarterial space of the patient comprises positioning the needle under CT guidance.